{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:20:48Z","timestamp":1787829648076,"version":"build-2784847793"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite guidelines recommending sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) for type 2 diabetes mellitus (T2DM) patients with cardiovascular risk, utilization remains low. This study evaluated the knowledge, attitudes, and practices (KAP) of physicians in Saudi Arabia toward these agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A nationwide cross-sectional study was conducted among 399 physicians in Saudi Arabia between December 2024 and November 2025. Participants completed an online survey assessing pharmacological knowledge, their attitude, and prescribing practices. Multivariable logistic regression was used to identify independent determinants of KAP outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Theoretical knowledge was high, with 91.0% of physicians demonstrating adequate knowledge of SGLT-2i and 78.4% for GLP-1RA. Conversely, only 23.6% held an overall positive attitude, while 75.4% met the threshold for appropriate practice. Notably, 90.0% of physicians identified medication availability and patient accessibility as constant prescribing barriers. Multivariable analysis showed that while knowledge scores were generally high, they did not independently guarantee a positive attitude. Older age was significantly associated with higher odds of inappropriate practice, whereas specialist status and higher attitude scores were linked to better clinical practices.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The study highlights a significant dissociation between high theoretical knowledge and attitudinal hesitancy among Saudi physicians. These findings suggest that under-prescribing may be associated more with attitudinal and structural factors, such as limited medication access, than with knowledge deficits. Future interventions should prioritize building clinical confidence through academic detailing and addressing systemic access issues to optimize evidence-based management for patients with T2DM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1929125","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T10:43:27Z","timestamp":1787827407000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Knowledge, attitudes, and practices of Saudi physicians toward the use of SGLT-2 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus: a nationwide cross-sectional study"],"prefix":"10.3389","volume":"17","author":[{"given":"Marwan A.","family":"Alrasheed","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, King Saud University","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bader M.","family":"Alhadhrami","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, King Saud University","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaziz A.","family":"Alqarni","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, King Saud University","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawaf M.","family":"Alghamdi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, King Saud University","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar A.","family":"Alfurayh","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, King Saud University","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar A.","family":"Almohammed","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, King Saud University","place":["Riyadh, Saudi Arabia"]},{"name":"Pharmacoeconomics Research Unit College of Pharmacy, King Saud University","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13061617","article-title":"The reasons for the low uptake of new antidiabetic drugs with cardiovascular effects: a family doctor perspective","volume":"13","author":"Kurevija","year":"2024","journal-title":"J Clin Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/jac.0000000000000379","article-title":"Cardiovascular disease in patients with type 2 diabetes: a qualitative analysis of knowledge, attitudes, and beliefs of health care professionals","volume":"44","author":"Ciemins","year":"2021","journal-title":"J Ambul Care Manage"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2019.0213","article-title":"Adoption of new glucose-lowering medications in the U.S.: the case of SGLT2 inhibitors: nationwide cohort study","volume":"21","author":"McCoy","year":"2019","journal-title":"Diabetes Technol Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2025.2145","article-title":"Sodium-glucose cotransporter 2 inhibitor use for heart failure in US ambulatory cardiovascular care","volume":"10","author":"El Rafei","year":"2025","journal-title":"JAMA Cardiol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2024-004431","article-title":"Recent trends in GLP-1 RA and SGLT2i use among people with type 2 diabetes and atherosclerotic cardiovascular disease in the USA","volume":"12","author":"King","year":"2024","journal-title":"BMJ Open Diabetes Res Care"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2024.08.026","article-title":"Prescribing patterns of SGLT2 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes at cardiology, endocrinology, and primary care visits","volume":"100","author":"Dixon","year":"2025","journal-title":"Mayo Clinic Proc"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2020.12.015","article-title":"Prescribing in type 2 diabetes patients with and without cardiovascular disease history: a descriptive analysis in the UK CPRD","volume":"43","author":"Farmer","year":"2021","journal-title":"Clin Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2337\/figshare.12020976.v1","article-title":"Patient and provider characteristics associated with sodium-glucose cotransporter 2 inhibitor prescription in patients with diabetes and proteinuric chronic kidney disease","volume":"38","author":"McCoy","year":"2020","journal-title":"Clin Diabetes"},{"key":"B14","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1186\/s12875-022-01928-z","article-title":"Factors affecting prescription of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus with established cardiovascular disease\/chronic kidney disease in Hong Kong: a qualitative study","volume":"23","author":"Ng","year":"2022","journal-title":"BMC Prim Care"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.1031306","article-title":"The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type two diabetes mellitus: a two-center retrospective cross-sectional study","volume":"10","author":"Korayem","year":"2022","journal-title":"Front Public Health"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/ph19010009","article-title":"Real-world prescribing patterns of SGLT2 inhibitors and GLP-1 receptor agonists in older adults with type 2 diabetes and cardiometabolic disease","volume":"19","author":"Alhomoud","year":"2026","journal-title":"Pharmaceuticals"},{"key":"B17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ahj.2020.03.017","article-title":"Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits","volume":"224","author":"Gao","year":"2020","journal-title":"Am Heart J"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01405-y","article-title":"Primary care physicians' knowledge of the cardiovascular effects of diabetes medications: findings from an online survey","volume":"37","author":"Shubrook","year":"2020","journal-title":"Adv Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2020.107813","article-title":"Global survey investigating causes of treatment inertia in type 2 diabetes cardiorenal risk management","volume":"35","author":"Kanumilli","year":"2021","journal-title":"J Diabetes Complications"},{"key":"B20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1471-2296-14-47","article-title":"Patient and physician related factors of adherence to evidence based guidelines in diabetes mellitus type 2, cardiovascular disease and prevention: a cross sectional study","volume":"14","author":"F\u00fcrthauer","year":"2013","journal-title":"BMC Fam Pract"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2174\/1573399820666230706125244","article-title":"Assessment of knowledge and perception of sodium-glucose co-transporter 2 (SGLT-2) inhibitors prescription among physicians in Saudi Arabia","volume":"20","author":"Somaili","year":"2024","journal-title":"Curr Diabetes Rev"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2337\/dc26-sint","article-title":"Introduction and methodology: Standards of care in diabetes\u20142024","volume":"47","author":"ElSayed","year":"2024","journal-title":"Diabetes Care"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2025.1706354","article-title":"Knowledge, attitudes, and practices of exercise rehabilitation in patients following percutaneous coronary intervention","volume":"12","author":"Wang","year":"2025","journal-title":"Front Cardiovasc Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0297335","article-title":"Knowledge, attitudes and practices towards COVID-19 among healthcare workers: a cross-sectional survey from Kiambu County, Kenya","volume":"19","author":"Juttla","year":"2024","journal-title":"PloS One"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0277506","article-title":"Knowledge, attitudes and preventive practices towards COVID-19 among workers at two points of entry in South-Eastern Botswana: a cross-sectional study","volume":"17","author":"Siamisang","year":"2022","journal-title":"PloS One"},{"key":"B26","doi-asserted-by":"publisher","first-page":"490","DOI":"10.2337\/figshare.22266835.v1","article-title":"Health care provider prescribing habits and barriers to use of new type 2 diabetes medications: a single-system survey study","volume":"41","author":"Yaseen","year":"2023","journal-title":"Clin Diabetes"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-1815","article-title":"Utilization rates of SGLT2 inhibitors and GLP-1 receptor agonists and their facility-level variation among patients with atherosclerotic cardiovascular disease and type 2 diabetes: insights from the Department of Veterans Affairs","volume":"45","author":"Mahtta","year":"2022","journal-title":"Diabetes Care"},{"key":"B28","volume-title":"Jardiance (Empagliflozin)","year":"2021"},{"key":"B29","volume-title":"Rybelsus (Semaglutide)","year":"2025"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70317","article-title":"PIONEER REAL Saudi Arabia: a multicentre, prospective, real-world study of once-daily oral semaglutide use in adults with type 2 diabetes in Saudi Arabia","volume":"28","author":"ElBadawi","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0165","article-title":"Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people","volume":"36","author":"Khunti","year":"2013","journal-title":"Diabetes Care"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.6139","article-title":"Association of race\/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US","volume":"4","author":"Eberly","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B33","doi-asserted-by":"publisher","first-page":"58","DOI":"10.18579\/jopcr\/v20i4.ms21083","article-title":"Knowledge, attitude and practice about a newer class of antidiabetic drug (glucagon-like peptide-1 receptor agonist) among the health care professionals of Qassim University, Saudi Arabia","volume":"20","author":"Aldhobaib","year":"2021","journal-title":"J Pharm Res"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1929125\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T10:43:28Z","timestamp":1787827408000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1929125\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":33,"alternative-id":["10.3389\/fendo.2026.1929125"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1929125","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"article-number":"1929125"}}